Influence of cyp2c19 genotypes on graft pathological findings and postoperative liver function in recipients after living-donor liver transplantation

Annals of Transplantation

Volumn 15, Issue 4, 2010, Pages 38-43

  Chiu, King Wah ^a   Nakano, Toshiaki ^a   Hu, Tsung Hui ^a   Tseng, Hui Peng ^a   Cheng, Yu Fan ^a   Jawan, Bruno ^a   Eng, Hock Liew ^a   Goto, Shigeru ^a   Chen, Chao Long ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CYP2C19; Living donor liver transplantation; Pathological finding; Postoperative liver function

Indexed keywords

CYTOCHROME P450 2C19;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT ATRESIA; CHILD; CLINICAL ARTICLE; END STAGE LIVER DISEASE; FEMALE; FULMINANT HEPATIC FAILURE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; INFANT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PATIENT CODING; POSTOPERATIVE PERIOD; PRIMARY BILIARY CIRRHOSIS;

ACUTE DISEASE; ADULT; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GRAFT REJECTION; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78651246514     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Daly AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol, 2003; 17(1): 27-41
2. Kóbori L, Kõhalmy K, Porrogi P et al: Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br J Clin Pharmacol, 2008; 65(3): 428-436
3. Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol, 1992; 22(1): 1-21
4. George J, Murray M, Byth K, Farrell GC: Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology, 1995; 21(1): 120-128
5. Elbekai RH, Korashy HM, El-Kadi AO: The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab, 2004; 5(2): 157-167
6. Frye RF, Zgheib NK, Matzke GR et al: Liver disease selectively modulates cytochrome P450 - mediated metabolism. Clin Pharmacol Ther, 2006; 80(3): 235-245
7. George J, Liddle C, Murray M et al: Pre-transplational regulation of Cytochrome P45o genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol, 1995; 49(7): 873-881
8. Hosohata K, Masuda S, Ogura Y et al: Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet, 2008; 23(2): 134-138
9. Chiu KW, Chen YS, de Villa VH et al: Characterization of liver enzymes on living related liver transplantation patients with acute rejection. Hepato- Gastroenterol, 2005; 52(66): 1825-1827
10. Liu S, Frye RF, Branch RA et al: Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. J Clin Pharmacol, 2005; 45(6): 666-673
11. Elmaagacli AH, Koldehoff M, Steckel NK et al: Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant, 2007; 40(7): 659-664
12. Löfgren S, Baldwin RM, Hiratsuka M et al: Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos, 2008; 36(5): 955-962
13. Cheung C, Yu AM, Chen CS et al: Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther, 2006; 316(3): 1328-1334
14. Lofgren SE, Baldwin MR, Carleros M et al: Regulation of human CYP2C18 and CYP2C19 in transgenic mice: Influence of castration, testosterone and growth Hormone. Drug Metab Dispos, 2009; 37(7): 1505-1512